3/2
08:28 am
cvkd
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]
Low
Report
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]
3/2
08:00 am
cvkd
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Low
Report
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
2/25
04:42 pm
cvkd
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events [Yahoo! Finance]
Medium
Report
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events [Yahoo! Finance]
2/24
08:30 am
cvkd
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
High
Report
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
1/12
08:00 am
cvkd
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibito
Medium
Report
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibito
12/30
07:07 pm
cvkd
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System [Yahoo! Finance]
Low
Report
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System [Yahoo! Finance]
12/29
08:12 am
cvkd
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On [Yahoo! Finance]
Medium
Report
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On [Yahoo! Finance]
12/17
09:00 am
cvkd
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
Medium
Report
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
12/11
08:27 am
cvkd
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) [Yahoo! Finance]
Medium
Report
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) [Yahoo! Finance]
12/11
08:05 am
cvkd
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Medium
Report
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)